Prana Biotechnology Ltd – Ameri (NASDAQ:PRAN) Short Interest Down by -10.30% – Currently Trading Up


Investors are more bullish recently as indicated by the downtick in short interest. The firm realized a fall in short interest from August 15, 2017 to August 31, 2017 of -10.30%. Short interest fell from 115,816 to 103,890 over that period. Days to cover increased 1.0 to 5.0 and the percentage of shorted shares was 0.07% on August 31.

Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Ubs Group Ag had sold a total of 3,198 shares trimming its position 89.4%. The value of the company’s investment in Prana Biotechnology Ltd – Ameri went from $11,000 to $1,000 a change of 90.9% for the reporting period. As of quarter end Citadel Advisors LLC had disposed of 11,211 shares trimming its holdings by 48.2%. The value of the investment in (PRAN) decreased from $38,000 to $28,000 a change of $10,000 since the last quarter.

As of quarter end Bank Of America Corp /de/ had disposed of a total of 166 shares trimming its stake by 15.1%. The value of the total investment in Prana Biotechnology Ltd – Ameri decreased from $3,000 to $2,000 decreasing 33.3% quarter over quarter.

The company is now up by 1.81%% since yesterday’s close of 2.76. Company shares last traded at $2.81 which is slightly above the 50 day moving average which is $2.66 and just above the 200 day moving average of $2.56. The 50 day moving average went up $0.15 or +5.64% whereas the 200 day average was up by +9.94%.

Prana Biotechnology Limited, launched on November 11, 1997, is a development-stage medical biotechnology company. The Company is involved in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. The Business’s lead product candidates are PBT2 and PBT434. The Business’s lead drug candidate PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. The Company also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders. PBT2 is a small molecule that reversibly binds and transports copper and zinc within neurons and across synapses..